Genprex, Inc. has announced its third-quarter financial results for the period ending September 30, 2026. This update is significant as it highlights the company's operational progress and financial health, which are critical for investors and stakeholders in the pharmaceutical industry.
Genprex, Inc., classified under the Standard Industrial Classification (SIC) code 2834, specializes in pharmaceutical preparations. The company trades on the Nasdaq under the ticker symbol GNPX. Established in Texas, Genprex focuses on developing innovative therapies, particularly for cancer treatment.
The recent filing, dated November 13, 2026, indicates that Genprex is making strides in its research and development efforts. However, specific financial details were not available in the SEC filing. The company aims to advance its pipeline of therapies, which could impact its market position and investor confidence.
This update may affect various stakeholders, including investors, healthcare professionals, and patients seeking new treatment options. The pharmaceutical preparations industry is highly competitive, and companies like Genprex are under constant pressure to innovate and deliver effective therapies.
As for what’s next, the filing does not specify any upcoming events or additional filings. Investors and industry observers will be keenly awaiting further announcements from Genprex regarding its ongoing projects and financial performance.
Financial Overview
As of September 30, 2026, Genprex, Inc. has authorized a total of 200,000,000 shares of common stock, with 1,219,141 shares issued and outstanding. The company has also authorized 10,000,000 shares of preferred stock, with none issued or outstanding as of the same date.
In terms of liabilities, the filing indicates that Genprex has derivative liabilities amounting to $22,500. This figure reflects the company's financial obligations and may influence its future financial strategies.
Research and Development Focus
Genprex continues to prioritize its research and development initiatives, particularly in the oncology sector. The company's ongoing projects are expected to contribute to advancements in cancer treatment, which is a significant area of interest for both investors and healthcare providers.
Future Reporting and Events
While the filing does not detail specific upcoming events or projections, stakeholders will be closely monitoring Genprex's future filings for insights into its strategic direction and financial health. The company is expected to provide updates on its clinical trials and any regulatory developments that may arise in the coming months.
Read Next
Madison Technologies reports Q3 results with net loss
Cyberloq Technologies Releases Q3 Results Amid Challenges
Specificity, Inc. Reports Q3 2026 Financial Results
SUNation Energy reports Q3 2026 financial results
Vystar Corp reports on Q3 performance in latest filing
Alpex Acquisition Corp Reports Quarterly Results










